Metastasis is a complex process in which malignant cancer cells from the breast spread into other regions of the body. Once metastasis has occurred, it is much more difficult to effectively treat breast cancer. Sometimes metastasis has occurred at the time the original breast cancer is diagnosed. However, in other cases, the metastasis of breast cancer is found months or even years after the initial treatment.
Breast Cancer Survival Rates for all types of breast cancers
Survival Rates for Breast Cancer
Steady rates of recurrence in women with estrogen receptor-positive disease could influence decisions about long-term therapy. Even 20 years after a diagnosis, women with a type of breast cancer fueled by estrogen still face a substantial risk of cancer returning or spreading, according to a new analysis from an international team of investigators published in the New England Journal of Medicine. Standard treatment for estrogen receptor-positive, or ER-positive, breast cancer includes five years of the endocrine-based treatments tamoxifen or aromatase inhibitors, both of which are taken daily as a pill. The patients all received endocrine therapy for five years and were free of cancer when they stopped therapy. Over the next 15 years, however, a steady number of these women saw their cancer spread throughout the body, as late as 20 years after the initial diagnosis.
The Risks of Breast Cancer Recurrence
Background: Quinquennial overviews of the randomised trials in early breast cancer have assessed the 5 year and year effects of various systemic adjuvant therapies on breast cancer recurrence and survival. Here, we report the year and year effects. Methods: Collaborative meta-analyses were undertaken of unconfounded randomised trials of adjuvant chemotherapy or hormonal therapy that began by Many trials involved CMF cyclophosphamide, methotrexate, fluorouracil , anthracycline-based combinations such as FAC fluorouracil, doxorubicin, cyclophosphamide or FEC fluorouracil, epirubicin, cyclophosphamide , tamoxifen, or ovarian suppression: none involved taxanes, trastuzumab, raloxifene, or modern aromatase inhibitors.
Breast cancer survival rates and prognosis are determined by so many different factors that it is always difficult to make generalizations. NOTE : this page has been recently updated with the most up-to-date statistics. Prognosis has improved so much because breast cancer treatments have become more effective since this page was first created. Remember that survival is better than listed here.